These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 29865060)
21. Subjective Cognitive Decline in Preclinical Alzheimer's Disease. Rabin LA; Smart CM; Amariglio RE Annu Rev Clin Psychol; 2017 May; 13():369-396. PubMed ID: 28482688 [TBL] [Abstract][Full Text] [Related]
22. Biomarkers, ketone bodies, and the prevention of Alzheimer's disease. VanItallie TB Metabolism; 2015 Mar; 64(3 Suppl 1):S51-7. PubMed ID: 25468143 [TBL] [Abstract][Full Text] [Related]
23. Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Counts SE; Ikonomovic MD; Mercado N; Vega IE; Mufson EJ Neurotherapeutics; 2017 Jan; 14(1):35-53. PubMed ID: 27738903 [TBL] [Abstract][Full Text] [Related]
24. The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. Szalárdy L; Zádori D; Klivényi P; Vécsei L J Alzheimers Dis; 2016 May; 53(2):373-92. PubMed ID: 27163812 [TBL] [Abstract][Full Text] [Related]
25. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. Cavedo E; Lista S; Khachaturian Z; Aisen P; Amouyel P; Herholz K; Jack CR; Sperling R; Cummings J; Blennow K; O'Bryant S; Frisoni GB; Khachaturian A; Kivipelto M; Klunk W; Broich K; Andrieu S; de Schotten MT; Mangin JF; Lammertsma AA; Johnson K; Teipel S; Drzezga A; Bokde A; Colliot O; Bakardjian H; Zetterberg H; Dubois B; Vellas B; Schneider LS; Hampel H J Prev Alzheimers Dis; 2014 Dec; 1(3):181-202. PubMed ID: 26478889 [TBL] [Abstract][Full Text] [Related]
29. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589 [TBL] [Abstract][Full Text] [Related]
30. Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study. Waragai M; Moriya M; Nojo T J Alzheimers Dis; 2017; 60(4):1411-1427. PubMed ID: 28968236 [TBL] [Abstract][Full Text] [Related]
32. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Vos SJB; Gordon BA; Su Y; Visser PJ; Holtzman DM; Morris JC; Fagan AM; Benzinger TLS Neurobiol Aging; 2016 Aug; 44():1-8. PubMed ID: 27318129 [TBL] [Abstract][Full Text] [Related]
33. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982 [TBL] [Abstract][Full Text] [Related]
35. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease]. Sakurai H; Hanyu H Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083 [TBL] [Abstract][Full Text] [Related]
36. [Suspected Non-Alzheimer's Disease Pathophysiology (SNAP) and Its Pathological Backgrounds in the Diagnosis of Preclinical and Clinical Alzheimer's Disease]. Yamada M Brain Nerve; 2018 Jan; 70(1):59-71. PubMed ID: 29348375 [TBL] [Abstract][Full Text] [Related]
37. Absence of practice effects in preclinical Alzheimer's disease. Hassenstab J; Ruvolo D; Jasielec M; Xiong C; Grant E; Morris JC Neuropsychology; 2015 Nov; 29(6):940-8. PubMed ID: 26011114 [TBL] [Abstract][Full Text] [Related]
38. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. Burnham SC; Raghavan N; Wilson W; Baker D; Ropacki MT; Novak G; Ames D; Ellis K; Martins RN; Maruff P; Masters CL; Romano G; Rowe CC; Savage G; Macaulay SL; Narayan VA; ; J Alzheimers Dis; 2015; 46(4):1079-89. PubMed ID: 26402634 [TBL] [Abstract][Full Text] [Related]
39. Global estimates on the number of persons across the Alzheimer's disease continuum. Gustavsson A; Norton N; Fast T; Frölich L; Georges J; Holzapfel D; Kirabali T; Krolak-Salmon P; Rossini PM; Ferretti MT; Lanman L; Chadha AS; van der Flier WM Alzheimers Dement; 2023 Feb; 19(2):658-670. PubMed ID: 35652476 [TBL] [Abstract][Full Text] [Related]
40. Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities. Caldwell CC; Yao J; Brinton RD Neurotherapeutics; 2015 Jan; 12(1):66-80. PubMed ID: 25534394 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]